Jpmorgan Chase & CO Chemo Centryx, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $3.44 Million - $8.03 Million	155,018 Added 276.52%	211,078 $10.9 Million
Q2 2022 Aug 11, 2022	SELL	$15.36 - $27.51 $961,167 - $1.72 Million	-62,576 Reduced 52.75%	56,060 $1.39 Million
Q1 2022 May 11, 2022	BUY	$22.22 - $39.12 $1.65 Million - $2.9 Million	74,101 Added 166.39%	118,636 $2.97 Million
Q4 2021 Feb 10, 2022	SELL	$18.38 - $40.5 $51,464 - $113,400	-2,800 Reduced 5.92%	44,535 $1.62 Million
Q3 2021 Nov 12, 2021	BUY	$13.18 - $19.83 $623,875 - $938,653	47,335 New	47,335 $809,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.